FDA Approves Gazyva (Obinutuzumab) for Treatment of Childhood-Onset Idiopathic Nephrotic Syndrome by Madaline Spencer| Published on: Oct 1, 2026

https://checkrare.com/fda-approves-gazyva-obinutuzumab-for-treatment-of-childhood-onset-idiopathic-nephrotic-syndrome/ The US Food and Drug Administration (FDA) has approved Gazyva (obinutuzumab) to reduce the risk of relapse in adult and pediatric patients 2 years of age and older with frequently relapsing or steroid dependent childhood-onset idiopathic nephrotic syndrome (INS) who are in complete remission. INS is a rare, autoimmune kidney disease characterized by unpredictable relapses that cause fatigue, swelling, weight gain and increased susceptibility to infections and clotting, as well as anxiety, depression and reduced self-esteem, brought on by the fear of relapse and social isolation. It is usually diagnosed in early childhood and is the most common form of primary glomerular disease in children. FDA Approves Gazyva for Idiopathic Nephrotic Syndrome, Offering a New Treatment Option by Madaline Spencer| Published on: Oct 14, 2026 Keisha L. Gibson, MD, MPH, pediatric nephrologist at the UNC School of Medicine, discusses the approval of Gazyva (obinutuzumab) for patients with childhood-onset idiopathic nephrotic syndrome (INS). https://checkrare.com/fda-approves-gazyva-for-idiopathic-nephrotic-syndrome-offering-a-new-treatment-option/